From BigGo Finance · BigGo Finance · · 1m 10s
JuveLook Patent Lawsuit Slows Baim Sale
Baim's $1.5 billion sale faces delay as Chinese patent lawsuit complicates deal terms.
In brief
Baim's $1.5 billion sale faces delay as Chinese patent lawsuit complicates deal terms. Baim's sale of its 89.53% stake to Premier Partners is delayed due to a Chinese patent infringement lawsuit filed by Regen Biotech. Originally reported by BigGo Finance.
Baim Sale Deal

Premier Partners sought to sell Baim's 89.53% controlling stake for 2 trillion won (approximately $1.5 billion).
Patent Lawsuit
Regen Biotech and IMEIK filed a patent infringement suit in a Chinese court tied to JuveLook's China rollout.
South Korean Patents
Baim's spray manufacturing patent was invalidated by South Korea's Supreme Court in 2021.
Baim Founder Connection

Baim's founder Kim Geun-pung is listed as an inventor on Regen Biotech's patent.
Bidders' Response
Some financial investors walked away from the auction after weighing litigation risk.
Patent Dispute Details
Regen Biotech filed a patent in 2009 for biodegradable polymer microparticles, while Baim filed a patent in 2015 for a network-structure polymer method.
Sale Impact
Bidders demand special indemnity clauses or escrow arrangements to mitigate litigation risk.
The big picture
Baim's sale of its 89.53% stake to Premier Partners is delayed due to a Chinese patent infringement lawsuit filed by Regen Biotech.
Read the TL;DR — this story on one card.





